MetaResponse Sciences

MetaResponse Sciences is a precision oncology company dedicated to improving cancer treatment outcomes through its proprietary functional diagnostic platform. The company's technology utilizes a rapid ex vivo assay to evaluate the real-time response of a patient's own tumor cells to various therapeutic agents, including chemotherapies and targeted biologics. By providing a direct measure of drug efficacy before treatment begins, MetaResponse aims to eliminate the trial-and-error approach in oncology and guide clinicians toward the most effective personalized therapies. The company focuses on high-need areas such as colorectal, pancreatic, and lung cancers, where standard-of-care responses are often unpredictable.